Wendy C Ziai1,2, Santosh B Murthy3, David J Roh4, Ifeyinwa S Asonye4, Fernanda Carvalho Poyraz4, Jessica R Magid-Bernstein5, Evan F Joiner6, Radhika Avadhani1, Issam Awad7, Daniel F Hanley1. 1. Brain Injury Outcomes Division (R.A., D.F.H., W.C.Z.), Johns Hopkins University School of Medicine, Baltimore, MD. 2. Division of Neurosciences Critical Care, Department of Neurology (W.C.Z.), Johns Hopkins University School of Medicine, Baltimore, MD. 3. Clinical and Translational Neuroscience Unit and Department of Neurology, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, NY (S.B.M.). 4. Department of Neurology (D.J.R., I.S.A., F.C.P.), Vagelos College of Physicians and Surgeons, Columbia University, NY. 5. Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, CT (J.R.M.-B.). 6. Department of Neurological Surgery (E.F.J.), Vagelos College of Physicians and Surgeons, Columbia University, NY. 7. Department of Neurological Surgery, University of Chicago School of Medicine, IL (I.A.).
Abstract
BACKGROUND: The objective of this study was to evaluate factors associated with intraventricular hemorrhage (IVH) expansion and its association with long-term outcomes. METHODS: We performed a post hoc analysis of the international, multi-center CLEAR III trial (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage) which enrolled IVH patients between September 1, 2009, and January 31, 2015. The exposure was IVH expansion, defined as >1 mL increase in volume between baseline and stability computed tomography scans, before treatment randomization. We assessed factors associated with IVH expansion and secondarily assessed the relationship of IVH expansion with clinical outcomes: composite of death or major disability (modified Rankin Scale score, >3), and mortality alone at 6 months. The relationship of IVH expansion on ventriculoperitoneal shunt placement was additionally explored. Multivariable logistic regression was used for all analyses. RESULTS: Of 500 IVH patients analyzed, the mean age was 59 (±11) years old, 44% were female and 135 (27%) had IVH expansion. In multivariable regression models, factors associated with IVH expansion were baseline parenchymal intracerebral hemorrhage (ICH) volume (adjusted odds ratio [OR], 1.04 per 1 mL increase [95% CI, 1.01-1.08]), presence of parenchymal hematoma expansion: >33% (adjusted OR, 6.63 [95% CI, 3.92-11.24]), time to stability head CT (adjusted OR, 0.71 per 1 hour increase [95% CI, 0.54-0.94]), and thalamic hematoma location (adjusted OR, 1.68 [95% CI, 1.01-2.79]) while additionally adjusting for age, sex, and race. In secondary analyses, IVH expansion was associated with higher odds of poor 6-month outcomes (adjusted OR, 1.84 [95% CI, 1.12-3.02]) but not mortality (OR, 1.40 [95% CI, 0.78-2.50]) after adjusting for baseline ICH volume, thalamic ICH location, age, anticoagulant use, Glasgow Coma Scale score, any withdrawal of care order, and treatment randomization arm. However, there were no relationships of IVH expansion on subsequent ventriculoperitoneal shunt placement (adjusted OR, 1.02 [95% CI, 0.58-1.80]) after adjusting for similar covariates. CONCLUSIONS: In a clinical trial cohort of patients with large IVH, acute hematoma characteristics, specifically larger parenchymal volume, hematoma expansion, and thalamic ICH location were associated with IVH expansion. Given that IVH expansion resulted in poor functional outcomes, exploration of treatment approaches to optimize hemostasis and prevent IVH expansion, particularly in patients with thalamic ICH, require further study. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00784134.
BACKGROUND: The objective of this study was to evaluate factors associated with intraventricular hemorrhage (IVH) expansion and its association with long-term outcomes. METHODS: We performed a post hoc analysis of the international, multi-center CLEAR III trial (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage) which enrolled IVH patients between September 1, 2009, and January 31, 2015. The exposure was IVH expansion, defined as >1 mL increase in volume between baseline and stability computed tomography scans, before treatment randomization. We assessed factors associated with IVH expansion and secondarily assessed the relationship of IVH expansion with clinical outcomes: composite of death or major disability (modified Rankin Scale score, >3), and mortality alone at 6 months. The relationship of IVH expansion on ventriculoperitoneal shunt placement was additionally explored. Multivariable logistic regression was used for all analyses. RESULTS: Of 500 IVH patients analyzed, the mean age was 59 (±11) years old, 44% were female and 135 (27%) had IVH expansion. In multivariable regression models, factors associated with IVH expansion were baseline parenchymal intracerebral hemorrhage (ICH) volume (adjusted odds ratio [OR], 1.04 per 1 mL increase [95% CI, 1.01-1.08]), presence of parenchymal hematoma expansion: >33% (adjusted OR, 6.63 [95% CI, 3.92-11.24]), time to stability head CT (adjusted OR, 0.71 per 1 hour increase [95% CI, 0.54-0.94]), and thalamic hematoma location (adjusted OR, 1.68 [95% CI, 1.01-2.79]) while additionally adjusting for age, sex, and race. In secondary analyses, IVH expansion was associated with higher odds of poor 6-month outcomes (adjusted OR, 1.84 [95% CI, 1.12-3.02]) but not mortality (OR, 1.40 [95% CI, 0.78-2.50]) after adjusting for baseline ICH volume, thalamic ICH location, age, anticoagulant use, Glasgow Coma Scale score, any withdrawal of care order, and treatment randomization arm. However, there were no relationships of IVH expansion on subsequent ventriculoperitoneal shunt placement (adjusted OR, 1.02 [95% CI, 0.58-1.80]) after adjusting for similar covariates. CONCLUSIONS: In a clinical trial cohort of patients with large IVH, acute hematoma characteristics, specifically larger parenchymal volume, hematoma expansion, and thalamic ICH location were associated with IVH expansion. Given that IVH expansion resulted in poor functional outcomes, exploration of treatment approaches to optimize hemostasis and prevent IVH expansion, particularly in patients with thalamic ICH, require further study. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00784134.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Ann Intern Med Date: 2007-10-16 Impact factor: 25.391
Authors: Wendy C Ziai; Carol B Thompson; Steven Mayo; Nichol McBee; William D Freeman; Rachel Dlugash; Natalie Ullman; Yi Hao; Karen Lane; Issam Awad; Daniel F Hanley Journal: Crit Care Med Date: 2019-08 Impact factor: 7.598
Authors: Andrew M Naidech; James Grotta; Jordan Elm; Scott Janis; Dar Dowlatshahi; Kazunori Toyoda; Thorsten Steiner; Stephan A Mayer; Pooja Khanolkar; Julie Denlinger; Heinrich J Audebert; Carlos Molina; Pooja Khatri; Nikola Sprigg; Achala Vagal; Joseph P Broderick Journal: Int J Stroke Date: 2021-09-05 Impact factor: 6.948
Authors: Lucia Rivera-Lara; Santosh B Murthy; Saman Nekoovaght-Tak; Hasan Ali; Nichol McBee; Rachel Dlugash; Malathi Ram; Richard Thompson; Issam A Awad; Daniel F Hanley; Wendy C Ziai Journal: Neurocrit Care Date: 2018-10 Impact factor: 3.210
Authors: Kenneth R Wagner; Frank R Sharp; Timothy D Ardizzone; Aigang Lu; Joseph F Clark Journal: J Cereb Blood Flow Metab Date: 2003-06 Impact factor: 6.200
Authors: Qi Li; Andrew D Warren; Adnan I Qureshi; Andrea Morotti; Guido J Falcone; Kevin N Sheth; Ashkan Shoamanesh; Dar Dowlatshahi; Anand Viswanathan; Joshua N Goldstein Journal: Ann Neurol Date: 2020-07-01 Impact factor: 11.274
Authors: Candice Delcourt; Shoichiro Sato; Shihong Zhang; Else Charlotte Sandset; Danni Zheng; Xiaoying Chen; Maree L Hackett; Hisatomi Arima; Jun Hata; Emma Heeley; Rustam Al-Shahi Salman; Thompson Robinson; Leo Davies; Pablo M Lavados; Richard I Lindley; Christian Stapf; John Chalmers; Craig S Anderson Journal: Neurology Date: 2017-02-24 Impact factor: 9.910